Literature DB >> 2152098

Transluminal angioplasty for treatment of vasospasm.

J M Eskridge1, D W Newell, G A Pendleton.   

Abstract

Angioplasty of symptomatic vasospasm can reverse neurologic deficits when performed soon after the onset of symptoms. Deficits including hemiparesis, aphasia, and depressed level of consciousness can resolve within 12 to 48 hours following angioplasty. Eleven of 15 patients had such a response in our series. All major intracranial vessels are amenable to treatment by this technique. Initial experience indicates the results are long lasting and the complication rate is low. This technique should prove to be a useful adjunct in the management of subarachnoid hemorrhage.

Entities:  

Mesh:

Year:  1990        PMID: 2152098

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  9 in total

1.  Endovascular management of cerebral aneurysms.

Authors:  A Berenstein
Journal:  Interv Neuroradiol       Date:  2004-10-22       Impact factor: 1.610

Review 2.  Intra-arterial papaverine infusions for the treatment of cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage.

Authors:  James K Liu; William T Couldwell
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 3.  Off-label use of drugs and devices in the neuroendovascular suite.

Authors:  M M Abdihalim; A E Hassan; A I Qureshi
Journal:  AJNR Am J Neuroradiol       Date:  2013-03-21       Impact factor: 3.825

4.  Critical care guidelines on the endovascular management of cerebral vasospasm.

Authors:  Matthew M Kimball; Gregory J Velat; Brian L Hoh
Journal:  Neurocrit Care       Date:  2011-09       Impact factor: 3.210

Review 5.  Management of cerebral vasospasm.

Authors:  R Loch Macdonald
Journal:  Neurosurg Rev       Date:  2006-02-24       Impact factor: 3.042

6.  Impact of percutaneous transluminal angioplasty for treatment of cerebral vasospasm on subarachnoid hemorrhage patient outcomes.

Authors:  Rakesh Khatri; Muhammad Zeeshan Memon; Haralabos Zacharatos; Ather M Taqui; Mushtaq H Qureshi; Gabriela Vazquez; M Fareed K Suri; Gustavo J Rodriguez; Ramachandra P Tummala; Mustapha A Ezzeddine; Adnan I Qureshi
Journal:  Neurocrit Care       Date:  2011-08       Impact factor: 3.210

Review 7.  Subarachnoid haemorrhage: epidemiology, risk factors, and treatment options.

Authors:  G J Kaptain; G Lanzino; N F Kassell
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

8.  Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm.

Authors:  Neeraj Badjatia; Mehmet A Topcuoglu; Johnny C Pryor; James D Rabinov; Christopher S Ogilvy; Bob S Carter; Guy A Rordorf
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

9.  Super-selective intra-arterial magnesium sulfate in combination with nicardipine for the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage.

Authors:  Qaisar A Shah; Muhammad Zeeshan Memon; M Fareed K Suri; Gustavo J Rodriguez; Osman S Kozak; Robert A Taylor; Ramachandra P Tummala; Gabriela Vazquez; Alexandros L Georgiadis; Adnan I Qureshi
Journal:  Neurocrit Care       Date:  2009-04-16       Impact factor: 3.210

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.